Ping An donates RMB10 million in anti-pandemic supplies to support Hong Kong
(Hong Kong, Shanghai, 3 March 2022) - Ping An Insurance (Group) Company of China, Ltd. (hereafter “Ping An” or the “Group”, HKEx:2318; SSE:601318) has donated COVID-19 diagnostic test kits and protective equipment worth RMB10 million to the Hong Kong SAR Government through the Ping An Foundation. Ping An is proud to support Hong Kong’s fight against the fifth wave of the COVID-19 pandemic and protect the health and safety of frontline medical staff and anti-pandemic workers.
Ping An has donated various supplies including COVID-19 diagnostic test kits, KN95 masks, protective clothing, face shields, surgical caps, shoe covers, and gloves. The supplies are expected to arrive in Hong Kong before March 15.
China is wholly committed to helping Hong Kong in the pandemic. Hong Kong and Shenzhen are inseparable from each other and will always bear trials and hardships together. Amid the pandemic outbreak in Hong Kong, Ping An, as a responsible corporate citizen, wants to support the fight against the pandemic to help meet the most urgent needs of frontline staff and medical workers.
Since the outbreak of the pandemic in 2020, Ping An has introduced several initiatives in insurance protection, public welfare donations and medical services. To date, Ping An has donated more than RMB180 million in supplies and cash. The Group has also provided more than RMB18 billion in financial support to affected enterprises, customers and frontline medical institutions. It has introduced innovative services such as an online end-to-end insurance policy process through a green claims channel and special pre-claims services, and extended insurance coverage to COVID-19 for policyholders. Ping An Good Doctor has provided free COVID-19 consultations and pandemic protection guidance for the public, attracting a total of 1.11 billion visits during the peak of the pandemic. Also, Ping An Healthcare Diagnostics Center is a designated institution for pandemic prevention and control. To date, its medical laboratories across China have performed nucleic acid tests for COVID-19 on more than 25 million samples.